Gene Therapy Viral Vectors Articles & Analysis
7 articles found
l Complex product formats: Bispecific antibodies, antibody-drug conjugates, and fusion proteins introduce unique purification challenges. l Gene and cell therapies: Large biomolecules like adeno-associated virus (AAV) or lentiviral vectors are difficult to purify at scale. ...
Viral vector-based gene therapy has now achieved good clinical results. ...
Why need viral vector characterization? Cell and gene therapies for various rare diseases are currently undergoing clinical trials worldwide. The rapid development in this field has led to an increase in regulatory scrutiny and product characterization requirements, as well as a bottleneck in viral ...
Researchers from Germany have recently developed a new technique that may be able to analyze and influence key stages of the HIV lifecycle, with the results of the study "Short- and long-range interactions in the HIV-1 5' UTR regulate genome dimerization and packaging" published in Nature Structural & Molecular Biology. Critical stages of the viral life cycle are appealing ...
and what makes them good candidates for gene therapy? Introduction In the first part of our three part series introducing AAV as a gene therapy vector, we talked about basic AAV vector biology. ...
The growing pipeline of cell and gene therapy therapies has led to an increase in demand for gene delivery vehicles such as plasmid DNA (pDNA), messenger RNA (mRNA) and viral vectors. ...
This post (the first in a three part series on AAV) provides an overview of AAV as a gene therapy vector, focusing primarily on the genetic and protein structure of an AAV capsid. ...